NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Background The autoimmune conditions involving GAD have been investigated for their association with several neurological disorders such as autism, Parkinson’s disease, schizophrenia, bipolar disorder, neuropathic pain, and epilepsy. The primary function of GAD65 is catalyzing glutamate to gamma amino butyric acid (GABA), which is further required for neurotransmission. Thus, targeting GAD65 and anti-GAD65 antibodies is of crucial importance for the improvement of the neuro-pathophysiology of various diseases. Methods The current work describes outcomes of initial MRI manifestations and immunotherapy in 15 Chinese patients developing anti-GAD65 autoimmune neurological syndromes. These patients received immunotherapy, a routine follow-up, and underwent serial MRI examinations (8 out of 15 patients). Results The findings from the MRI examination demonstrated dynamic changes in imaging with the progression of anti-GAD65 associated disease, which can be further classified into cortical/subcortical parenchymal type and mesial temporal lobe (MTL) type. Additionally, early initiation of immunotherapy showed significant improvement in symptoms, imaging findings, and prognosis, especially in patients with cortical/subcortical MRI changes. Conclusion The disease prognosis can be significantly improved over conventional strategies with the help of combining early immunotherapy and dynamic MRI monitoring.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.